BioInvent: Option and License Deal with Exelixis - Redeye
Redeye views the deal with Exelixis, which provides BioInvent with a USD 25m upfront fee, as a useful cash injection and another validation of its core platform technologies.
ANNONS
Redeye views the deal with Exelixis, which provides BioInvent with a USD 25m upfront fee, as a useful cash injection and another validation of its core platform technologies.